SHATTUCK LABS INC (STTK)

Company Profile

Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 75 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. The company is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. The company has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. The company has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Company Info

SHATTUCK LABS INC

500 W. 5Th Street, Suite 100

Austin TEXAS 78703

P: 15129004690

CEO: Taylor Schreiber

Employees: 75

Website: https://www.shattucklabs.com/